Fox Chase Cancer Center Postdoctoral Associate Emma Guilbaud Selected as Forbeck Scholar

Thumbnail
Emma Guilbaud, PhD, a postdoctoral associate at Fox Chase Cancer Center.

PHILADELPHIA (January 29, 2025) — Emma Guilbaud, PhD, a postdoctoral associate at Fox Chase Cancer Center, has been selected as a Forbeck Scholar by the William Guy Forbeck Research Foundation. This prestigious appointment recognizes early career cancer researchers for their achievements, research, and dedication to the field.

“Being named a Forbeck Scholar is a tremendous honor,” said Guilbaud. “This recognition will support my efforts to improve the immune response of breast cancer when exposed to radiation therapy.”

The Forbeck Scholarship recognizes exceptional young oncologists who are making transformative strides in cancer research. The scholarship was established to foster innovation and collaboration in oncology by supporting studies with the potential to significantly impact patient outcomes.  

Guilbaud is currently a postdoctoral associate in the laboratory of Lorenzo Galluzzi, PhD, an Associate Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase, where she focuses on how breast cancer cells respond to mitochondrial stress during radiation therapy.

The Cancer Signaling and Microenvironment Research Program plays a vital role in advancing the understanding of cancer biology by investigating cancer cell-intrinsic signaling adaptations and their interactions with the microenvironment.

Prior to joining Fox Chase in 2022, Guilbaud completed her doctorate in clinical and therapeutic research at the Mediterranean Center of Molecular Medicine in Nice, France. She also holds a Bachelor of Science in molecular biology and genetics and a Master of Science in genetics, immunology, and animal development from the University of Côte d’Azur.

Guilbaud’s current research has shown that combining radiation therapy with specific drugs can activate the immune system, improving its ability to fight cancer. By targeting these processes, she aims to enhance the effectiveness of current cancer treatments.  

Being named a Forbeck Scholar will provide Guilbaud with resources to further her research. With these additional tools, she aims to identify more effective treatment strategies that can help overcome immune evasion by cancer cells. 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text